Company news

BELLUS Health Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

June 28, 2023

BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences

April 4, 2019

BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients

April 3, 2019

BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan

February 21, 2019

BELLUS Health Updates BLU-5937 Top-Line Phase 1 Results Timeline to November 2018

November 14, 2018

BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937

October 31, 2018

BELLUS Health Announces Appointment of Clinical Advisory Board

September 25, 2018

BELLUS Health to Present at Baird 2018 Global Healthcare Conference

August 30, 2018

BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2018

August 8, 2018

BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937

July 19, 2018

BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937

July 9, 2018

BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium

June 27, 2018

BELLUS Health to Present at the 2018 International Cough Symposium

June 20, 2018

BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018

May 15, 2018

BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity

April 30, 2018

BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference

April 26, 2018

BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017

February 21, 2018

BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals

January 9, 2018

BELLUS Health to Present at Biotech Showcase(TM) 2018 Conference

January 4, 2018

BELLUS Health Closes $20M Common Share Financing

December 12, 2017

BELLUS Health Announces Pricing of up to $20M Equity Offering

December 5, 2017

BELLUS Health Announces Overnight Marketed Equity Offering

December 4, 2017

BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017

November 8, 2017

BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors

September 27, 2017

BELLUS Health Chronic Cough Webcast Taking Place Today

September 20, 2017

BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models

September 18, 2017

BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017

September 6, 2017

BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017

August 9, 2017

BELLUS Health announces closing of the sale of its equity interest in FB Health for total consideration up to CA$2.5M

July 3, 2017

BELLUS Health announces sale of its equity interest in FB Health for total consideration up to CA$2.5M

June 19, 2017

BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2017

May 9, 2017

BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference

April 27, 2017

BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough

April 24, 2017

BELLUS Health Announces the Sale of Subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals

March 16, 2017

Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016

February 28, 2017

BELLUS Health and The NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough

February 28, 2017

Bellus Health Announces Payment to Thallion CVR Holders

February 17, 2017

BELLUS Health provides update on pipeline

December 21, 2016

BELLUS Health reports financial and operating results for the third quarter ended September 30, 2016

November 10, 2016

BELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Results for the Second Quarter Ended June 30, 2016

August 9, 2016

BELLUS Health announces top-line Phase 3 results of KIACTA(TM) for the treatment of AA amyloidosis

June 20, 2016

BELLUS Health and Pharmascience announce scheduled conversion of Pharmascience's interest in BHI Limited Partnership

June 2, 2016

BELLUS Health reports financial and operating results for the first quarter ended March 31, 2016

May 12, 2016

Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2015

February 24, 2016

Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA(TM) for the Treatment of Orphan Disease AA Amyloidosis

January 21, 2016

Bellus Health announces scheduled settlement of convertible notes

January 1, 2016

BELLUS Health reports financial and operating results for the third quarter ended September 30, 2015

November 12, 2015

BELLUS Health announces oral and poster presentations highlighting Shigamab(TM) for the treatment of hemolytic uremic syndrome

September 9, 2015

BELLUS Health narrows timelines for the Phase III study for KIACTA™ and reports financial and operating results for the second quarter ended June 30, 2015

August 12, 2015

Bellus Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2015

May 12, 2015

Older news releases →

Decks